EcoDrugPlus

Bcl2 Apoptosis Regulator

Ensembl ID : ENSMMMG00000002828
Gene Symbol: BCL2
3 Cross references
227 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSMMMG00000023798
Gene Symbol: BCL2L1
2 Cross references
284 Possible Orthologues:

Bcl2 Like 2

Ensembl ID : ENSMMMG00000013458
Gene Symbol: BCL2L2
3 Cross references
64 Possible Orthologues:

Bcl2 Related Protein A1

Ensembl ID : ENSMMMG00000000627
Gene Symbol: BCL2A1
3 Cross references
114 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSMMMG00000024436
Gene Symbol: BCR
3 Cross references
274 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSMMMG00000015780
Gene Symbol: BTK
3 Cross references
206 Possible Orthologues:

C-C Motif Chemokine Receptor 1

Ensembl ID : ENSMMMG00000007155
Gene Symbol: CCR1
3 Cross references
299 Possible Orthologues:

C-C Motif Chemokine Receptor 2

Ensembl ID : ENSMMMG00000007144
Gene Symbol: CCR2
3 Cross references
286 Possible Orthologues:

C-C Motif Chemokine Receptor 4

Ensembl ID : ENSMMMG00000013862
Gene Symbol: CCR4
3 Cross references
254 Possible Orthologues:

C-C Motif Chemokine Receptor 5

Ensembl ID : ENSMMMG00000007137
Gene Symbol: CCR5
3 Cross references
298 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSMMMG00000008554
Gene Symbol: CCR9
1 Cross references
262 Possible Orthologues:

C-X-C Motif Chemokine Ligand 8

Ensembl ID : ENSMMMG00000024698
Gene Symbol: CXCL8
3 Cross references
183 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).